Li Ke, Khan Dilaware, Fischer Igor, Muhammad Sajjad
Department of Neurosurgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Department of Neurosurgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; Department of Neurosurgery, King Edward Medical University, Lahore, Pakistan; Department of Neurosurgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
World Neurosurg. 2024 Nov;191:e186-e205. doi: 10.1016/j.wneu.2024.08.095. Epub 2024 Sep 7.
Aneurysmal subarachnoid hemorrhage (aSAH) is often complicated by cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI), which significantly impact patient outcomes. The study aimed to investigate the predictive value of systemic serum biomarker levels for CVS and DCI following aSAH.
We retrospectively analyzed data for 450 aSAH patients admitted to University Hospital Düsseldorf between January 2011 and October 2021. Serum biomarkers were measured on admission. The occurrence of CVS and DCI was assessed based on clinical and radiological criteria. Multivariate logistic regression analysis was performed to determine the independent association of serum biomarkers with CVS and DCI. We compared the predictive values of various models using the area under the receiver operating characteristic curve.
Of the 450 patients, 126 (28.0%) developed CVS, 123 (27.3%) developed DCI, and 62 (13.8%) developed co-occurring CVS and DCI. Patients with CVS, DCI, or both had significantly higher admission C-reactive protein (CRP) levels than those without these complications (P < 0.001). Elevated CRP levels were independently associated with an increased risk of CVS, DCI, and co-occurring CVS and DCI (P < 0.05). CRP demonstrated a higher predictive value for CVS (area under the curve [AUC]: 0.811) and co-occurring CVS and DCI (AUC: 0.802) compared to DCI alone (AUC: 0.690).
Our findings suggest that admission systemic CRP levels can serve as a more valuable predictor for developing CVS than DCI following aSAH. Incorporating CRP into clinical assessments may aid in risk stratification and early intervention strategies for patients at high risk of these complications.
动脉瘤性蛛网膜下腔出血(aSAH)常并发脑血管痉挛(CVS)和迟发性脑缺血(DCI),这对患者预后有显著影响。本研究旨在探讨全身血清生物标志物水平对aSAH后CVS和DCI的预测价值。
我们回顾性分析了2011年1月至2021年10月期间杜塞尔多夫大学医院收治的450例aSAH患者的数据。入院时检测血清生物标志物。根据临床和影像学标准评估CVS和DCI的发生情况。进行多因素逻辑回归分析以确定血清生物标志物与CVS和DCI的独立关联。我们使用受试者操作特征曲线下面积比较了各种模型的预测价值。
在450例患者中,126例(28.0%)发生CVS,123例(27.3%)发生DCI,62例(13.8%)同时发生CVS和DCI。发生CVS、DCI或两者皆有的患者入院时C反应蛋白(CRP)水平显著高于未发生这些并发症的患者(P < 0.001)。CRP水平升高与CVS、DCI以及同时发生CVS和DCI的风险增加独立相关(P < 0.05)。与单独的DCI(曲线下面积[AUC]:0.690)相比,CRP对CVS(AUC:0.811)和同时发生CVS和DCI(AUC:0.802)具有更高的预测价值。
我们的研究结果表明,与aSAH后发生DCI相比,入院时全身CRP水平可作为发生CVS更有价值的预测指标。将CRP纳入临床评估可能有助于对这些并发症高危患者进行风险分层和早期干预策略。